Increased Risk of Cancer in relation to Gout: A Review of Three Prospective Cohort Studies with 50,358 Subjects

Weijie Wang,1 Donghua Xu,2,3 Bin Wang,4 Shushan Yan,3,5 Xiaochen Wang,3 Yin Yin,3 Xuehao Wang,3 Beicheng Sun,3 and Xiaoyang Sun1

1 Department of Neurosurgery, Huai'an First People's Hospital Affiliated to Nanjing Medical University, 6 Beijing Road West, Huai'an 223300, China
2 Department of Rheumatology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
3 Liver Transplantation Center of the First Affiliated Hospital and State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210002, China
4 Department of Endocrinology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China
5 Department of Surgical Oncology, The Eighty-First Hospital of People's Liberation Army, Nanjing 210002, China

Correspondence should be addressed to Beicheng Sun; beichengsun_doc@aliyun.com and Xiaoyang Sun; xiaoyangdoc@yeah.net

Received 15 July 2014; Revised 1 September 2014; Accepted 10 September 2014

Abstract

Gout is a common inflammatory disease characterized by acute arthritis and hyperuricemia due to disorder of purine metabolism [1]. It is caused by monosodium urate crystal deposition in tissues leading to arthritis, soft tissue masses, kidney stones, and urate nephropathy. Attacks of pain, erythema, and swelling of one or a few joints in the lower extremities are prominent clinical manifestations of acute gout. Higher intakes of red meat, fructose and beer, alcohol consumption, and genetic polymorphisms have been implicated in the development of gout and hyperuricemia [2–4]. The prevalence of gout is increasing worldwide. It is more common in men and strongly age-related. To the best of our knowledge, gout is highly related to obesity, hypertension, diabetes mellitus, chronic kidney, and cardiovascular diseases [1, 2, 5].

During the past few years, the association between cancer and gout as well as hyperuricemia has drawn a lot of attention. High cell turnover can lead to hyperuricemia and tumorigenesis, implicating an underlying link between purine metabolism disorders and cancer [6]. It has been well documented that high serum uric acid levels are independently related to an increased risk of cancer [7–9]. In addition, massive lysis of malignant cells in certain patients with tumor lysis syndrome can result in hyperuricemia, which can predispose patients to renal failure, coronary heart disease, and gout [10, 11]. Interestingly, uric acid has also...
been hypothesized to play a protective role in carcinogenesis due to its systemic antioxidant properties [12]. Nonetheless, this issue remains controversial. Taken together, all available data support the hypothesis of a link between metabolic syndrome and tumorigenesis.

Although recent epidemiological studies have sparked interest in the hypothesis, the precise association between gout and cancer risk remains obscure. Our study was firstly aimed to investigate this association by meta-analysis of all currently available data.

2. Materials and Methods

2.1. Search Strategy. We performed a comprehensive literature search in PubMed and Embase databases from their inception up to July 1, 2014, for studies on the association between gout and cancer risk. The following search terms were used: gout, or hyperuricemia; cancer, tumor, or carcinoma; risk, or incidence. The references of retrieved studies were also screened for additional publications. No language restriction was imposed.

2.2. Inclusion and Exclusion Criteria. The included studies must meet the inclusion criteria as follows: (1) studies concerning the association between gout and cancer risk; (2) studies in a cohort design; (3) studies with enough information for odds ratio (ORs), relative risks (RRs), or hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs).

Studies were excluded if they were (1) publications not related to the role of gout in cancer risk; (2) case-only study; (3) case report; (4) reviews; (5) animal studies; (6) studies with overlapping data.

2.3. Data Extraction. Two investigators independently extracted available data from all studies as follows: first author’s name, year of publication, origins, diagnosis of patients, study design, type of cancers, total sample size, study period, adjusted factors, baseline time, follow-up duration, mean age of gout patients, and RRs or HRs or ORs with corresponding 95% CIs. Disagreements were resolved by consensus.

2.4. Statistical Analysis. The strength for relationship between gout and cancer risk was estimated by calculating the pooled RRs with 95% CIs. The between-study heterogeneity was evaluated by Cochran’s Q-statistic test and $I^2$ test [14, 15]. $P < 0.05$ and $I^2 > 50\%$ implicated potential between-study heterogeneity among studies. The fixed-effects model by Mantel and Haenszel method was used if the between-study heterogeneity was not statistically significant [16]; otherwise, the random-effects model by way of DerSimonian and Laird was applied with regard to significant between-study heterogeneity [17]. Subgroup analyses by different type of cancer and sensitivity analysis were also carried out to assess the association. Begg’s funnel plots and Egger’s test were conducted to estimate possible publication bias in our study [18, 19]. The STATA 12.0 software (StataCorp, College Station, TX, USA) was used. All $P$ values were two-tailed, and $P < 0.05$ suggested statistical significance.

3. Results

3.1. Characteristics of All Eligible Studies. After a comprehensive literature search, three prospective cohort studies with a total of 50, 358 subjects were retrieved for meta-analysis [6, 13, 20]. The study by Boffetta et al. was divided into two independent studies according to gender. The characteristics of included studies were summarized in Table 1 mainly including the name of the first author, publication year, baseline time, follow-up duration, type of cancer, adjusted factors, and mean age of gout patients. The effect of gout on cancer was primarily evaluated in the development of urological cancers, digestive system cancers, lung cancer, breast cancer, and brain tumors (Table 1).

3.2. Association between Gout and Cancer Risk. Gout was related to a significantly increased risk of cancer as suggested by overall analysis of four independent cohort studies (RR = 1.42, 95% CI 1.09–1.84, $P = 0.008$) (Table 2, Figure 1). However, the between-study heterogeneity was significant ($I^2 = 98.1\%, P < 0.001$). Besides, no significant association between gout and total cancer risk was observed in the male population, supported by the pooled RR (RR = 1.67, 95% CI 0.93–3.01, $P = 0.087$) (Table 2). Sensitivity analysis did not alter the pooled results (data not shown).

An elevated risk of urological cancers was observed to be associated with gout, although obvious heterogeneity existed among included studies (RR = 1.72, 95% CI 1.30–2.26, $P < 0.001$; $I^2 = 90.7\%, P < 0.001$) (Table 2).

For the risk of digestive system cancers, the pooled RRs suggested that gout exerted risk effect on the development of digestive system cancers (RR = 1.39, 95% CI 1.23–1.56, $P < 0.001$; $I^2 = 68.2\%, P < 0.001$) (Table 2).

A modest association between gout and lung cancer risk was demonstrated, which suggested a risk factor of gout for the development of lung cancer (RR = 1.29, 95% CI 1.01–1.65, $P = 0.039$; $I^2 = 75.5\%, P = 0.007$) (Table 2).

No significant relationship between gout and the risk of breast cancer or brain cancer was observed in our study (Table 2).

3.3. Publication Bias. Begg’s funnel plots and Egger’s test did not show any evidence for publication bias risk in the present meta-analysis (data not shown).

4. Discussion

The present meta-analysis based on three prospective cohort studies shows the evidence that gout confers risk effect on carcinogenesis, particularly in urological cancers, digestive system cancers, and lung cancer. Besides, gout did not modify the risk of breast cancer or brain cancer or total cancer risk in males, as suggested by the pooled RRs, respectively. Nevertheless, the findings about breast and brain cancers risk
Table 1: Characteristics of all studies.

| Study               | Year  | Origins | Number of subjects | Follow-up duration (years) | Baseline time | Mean age of patients | Cancer sites                                                                 | Adjusted factors                                                                 |
|---------------------|-------|----------|--------------------|----------------------------|---------------|----------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Chen et al. [13]    | 2014  | Taiwan   | 9,413              | 8                          | 1998–2000     | 51.03 ± 14.52        | Prostate, bladder, kidney, colorectum, liver, gallbladder and bile duct, stomach, lung, esophageal, pancreas, nasopharyngeal, brain, and oral, and so forth | Age, sex, year, and month of first diagnosis                                      |
| Kuo et al. [6]      | 2012  | Taiwan   | 24,088             | 7.8-7.9                    | 2000–2008     | 42.3 ± 16.3          | Prostate, bladder, colon, liver, stomach, lung, and breast, and so forth     | Age and sex                                                                      |
| Bofetta et al. [20] | Men   | Sweden   | 10,500             | NR                        | 1965–1995     | NR                   | Bladder, kidney, rectum, colon, liver and bile duct, stomach, lung, pancreas, brain, and oral, and so forth | Sex, time since first hospitalization, and gout as primary or the only diagnosis |
|                     | Women | Sweden   | 6,357              | NR                        | 1965–1995     | NR                   | Bladder, kidney, rectum, colon, liver and bile duct, stomach, lung, pancreas, brain, oral, breast, and so forth | Sex, time since first hospitalization, and gout as primary or the only diagnosis |

Table 2: Summary of meta-analysis results.

| Type of cancer                  | ^aRR [95% CI] | P value for pooled analysis | I² (%) | P value for heterogeneity analysis |
|---------------------------------|---------------|----------------------------|--------|----------------------------------|
| All                             | 1.42 [1.09–1.84] | 0.008                      | 98.1   | <0.001                           |
| Males                           | 1.67 [0.93–3.01] | 0.087                      | 99.0   | <0.001                           |
| Urological cancers              | 1.72 [1.30–2.26] | <0.001                     | 90.7   | <0.001                           |
| Digestive system cancers        | 1.39 [1.23–1.56] | <0.001                     | 68.2   | <0.001                           |
| Lung cancer                     | 1.29 [1.01–1.65] | 0.039                      | 75.5   | 0.007                            |
| Breast cancer                   | 0.92 [0.77–1.09] | 0.336                      | 45.9   | 0.174                            |
| Brain cancer                    | 1.24 [0.82–1.87] | 0.309                      | 0.0    | 0.946                            |

^aRR, relative risk; 95% CI, 95% confidence interval.

must be interpreted with caution due to limited sample size. Sensitivity analysis did not materially alter the pooled results.

Gout is a disorder of purine metabolism, which has been suggested in relation to many kinds of diseases, such as end-stage renal disease, myocardial infarction, obesity, and diabetes, due to increased serum uric acid [21–24]. Kuo et al. have reported that gout is an independent risk factor for myocardial infarction even in young people and those without cardiovascular risk factors [22]. Gout patients aged 50 years or above were more likely to die from cardiovascular diseases than those without gout, although they had no preceding serious cardiovascular diseases [25]. Therefore, gout is positively associated with cardiovascular disease risk and mortality. Hyperuricemia is a common clinical presentation of gout and is usually attributed to high cell turnover and accelerated purine breakdown. Despite the antioxidant properties of uric acid in preventing the formation of carcinogenic oxygen radicals, little evidence supports its role in protecting against cancer [8, 12, 26]. Hyperuricemia is a rare complication in cancer and is especially common in patients with hematological malignancies, for instance, acute lymphocytic leukemia and Burkitt lymphoma [27, 28]. Given the hypothesis of link between metabolism syndrome and cancer, many studies have investigated roles of serum uric acid, hyperuricemia, and gout in carcinogenesis and cancer mortality [6, 7, 13, 20, 29, 30]. Kolonel and colleagues firstly elucidated that high level of serum uric acid exerted risk effect on prostate carcinogenesis, but not the development of overall cancer and cancers of stomach, colon, rectum, lung, bladder, or hematopoietic system [31]. Serum uric acid was not an independent risk factor for cancer mortality; however, it could predispose diabetes to die, which suggested an interactive effect of uric acid with diabetes on the risk of death from cancer [32]. Similarly, hyperuricemia was not
Table 1: Mediators of Inflammation

| Study ID          | RR (95% CI)         | Weight (%) |
|-------------------|---------------------|------------|
| All               | 2.26 (2.05, 2.48)   | 3.49       |
| Chen et al.       | 3.44 (2.13, 4.64)   | 2.21       |
| Chen et al.       | 1.07 (0.83, 1.38)   | 2.85       |
| Boffetta et al. (1) | 1.09 (0.84, 1.39)  | 2.86       |
| Boffetta et al. (2) | 1.57 (0.90, 2.55)  | 1.69       |
| Boffetta et al. (1) | 2.31 (1.41, 3.78)  | 1.79       |
| Boffetta et al. (2) | 1.68 (1.18, 2.32)  | 2.45       |
| Boffetta et al. (2) | 1.95 (1.07, 3.27)  | 1.57       |
| Chen et al.       | 3.35 (2.58, 4.37)   | 2.80       |
| Kuo et al.        | 1.71 (1.45, 2.02)   | 3.24       |
| Boffetta et al. (1) | 1.07 (0.94, 1.20)  | 3.41       |
| Subtotal (I² = 90.7%, P = 0.000) | 1.72 (1.30, 2.26) | 24.86     |
| Digestive system cancers |         |           |
| Kuo et al.        | 1.12 (0.98, 1.27)   | 3.38       |
| Boffetta et al. (1) | 1.29 (1.02, 1.60)  | 2.98       |
| Boffetta et al. (2) | 1.26 (0.91, 1.69)  | 2.58       |
| Chen et al.       | 2.25 (1.81, 2.79)   | 3.02       |
| Chen et al.       | 1.69 (0.99, 2.88)   | 1.65       |
| Kuo et al.        | 1.12 (0.99, 1.28)   | 3.38       |
| Boffetta et al. (1) | 2.08 (1.45, 2.90)  | 2.41       |
| Boffetta et al. (2) | 1.59 (0.96, 2.48)  | 1.86       |
| Chen et al.       | 1.90 (1.50, 2.40)   | 2.94       |
| Chen et al.       | 1.53 (0.94, 2.47)   | 1.83       |
| Chen et al.       | 1.30 (0.91, 1.85)   | 2.37       |
| Boffetta et al. (1) | 1.74 (1.20, 2.44)  | 2.37       |
| Boffetta et al. (2) | 0.78 (0.21, 2.00)  | 0.57       |
| Chen et al.       | 1.64 (0.78, 3.56)   | 1.03       |
| Boffetta et al. (1) | 1.35 (0.99, 1.92)  | 2.28       |
| Boffetta et al. (2) | 1.01 (0.52, 1.77)  | 1.41       |
| Boffetta et al. (1) | 1.20 (0.89, 1.57)  | 2.70       |
| Boffetta et al. (2) | 1.25 (0.78, 1.92)  | 1.95       |
| Chen et al.       | 1.80 (1.17, 2.75)   | 2.05       |
| Kuo et al.        | 1.18 (0.97, 1.43)   | 3.12       |
| Boffetta et al. (1) | 0.97 (0.71, 1.30)  | 2.61       |
| Boffetta et al. (2) | 1.11 (0.65, 1.78)  | 1.75       |
| Subtotal (I² = 68.2%, P = 0.000) | 1.39 (1.23, 1.56) | 50.26     |
| Lung cancer       |         |           |
| Chen et al.       | 1.77 (1.38, 2.27)   | 2.87       |
| Kuo et al.        | 1.07 (0.94, 1.23)   | 3.36       |
| Boffetta et al. (1) | 1.24 (1.00, 1.53)  | 3.04       |
| Boffetta et al. (2) | 1.20 (0.64, 2.05)  | 1.49       |
| Subtotal (I² = 75.5%, P = 0.007) | 1.29 (1.01, 1.65) | 10.77     |
| Overall (I² = 88.6%, P = 0.000) | 1.45 (1.32, 1.59) | 100.00    |

Note: weights are from random effects analysis

Figure 1: Forest plot for gout and cancer risk.

associated with the RRs of cancer-related death [30]. Taken together, the effect of serum uric acid on cancer risk and mortality remains inconclusive.

Up till now, three prospective cohort studies with a total of 50,358 subjects have been performed to evaluate the association between gout and cancer risk [6,13,20]. Nonetheless, the findings were conflicting and inconclusive. Boffetta et al. reported that gout patients were at an elevated risk of overall cancer and cancers of the oral cavity and pharynx, colon, liver and biliary tract, pancreas, lung, skin, endometrium, and kidney, as well as of malignant melanoma among both males and females [20]. The study provided no evidence of a protective role of serum uric acid in carcinogenesis [20]. The findings demonstrated by Kuo et al. were consistent with those of Boffetta et al. [6]. However, no increased risk of liver, colon, lung, stomach, bladder, and breast cancers was observed in gout patients, respectively [6]. The study by Chen et al. showed that gout patients were more likely to
develop most cancers including cancers of prostate, bladder, kidney, colorectum, liver, gallbladder and biliary tract, lung, and stomach [13]. The significant association between gout and increased risk of overall cancer in those studies was not likely generated due to chance. Nevertheless, concerning the risk of individual cancers, bias might be introduced because of small sample size of certain cases. We performed a meta-analysis of all published studies in relation to the role of gout in cancer risk. The pooled RRs suggested that gout was a risk factor for carcinogenesis, especially the development of urological cancers, digestive system cancers, and lung cancer. The effect of gout on brain cancer and breast cancer warrants further investigation by more epidemiological studies with large sample size.

5. Limitations

Some limitations must be seriously considered. Firstly, only three cohort studies were included into our study, but the statistical power was sufficient in estimating the role of gout in carcinogenesis. More relevant studies on the association between gout and individual cancers risk, especially brain and breast cancers, are warranted for further investigation. Secondly, adjusted factors of all included studies were not consistent. Thus, bias might be introduced in our study because of confounding factors such as age, sex, and ethnicity. Future studies based on adjusted analysis are encouraged to investigate the effect of gout disease on cancer risk. Thirdly, the influence of gout disease duration in tumorigenesis was elucidated in a recent study [13]. We failed to estimate cancer risk related to the duration of gout, because relevant epidemiological studies were limited. Last but not the least, cancer is a multifactorial disease with complex pathogenic factors including genetic polymorphisms, environmental carcinogens, and history of family as well as chronic inflammatory diseases [33]. An interactive effect between gout and other carcinogenic factors may be critical in carcinogenesis, which warrants further elucidation.

6. Conclusions

In summary, our study does show evidence for the hypothesis of a link between gout and carcinogenesis. It suggests that gout is an independent risk factor for the incidence of total cancer, particularly urological cancers, digestive system cancers, and lung cancer. The precise association between gout and individual cancers warrants further investigation by more epidemiological studies with high quality.

Abbreviations

RRs: Relative risks
ORs: Odds ratio
HRS: Hazard ratios
95% CIs: 95% confidence intervals.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Weijie Wang, Donghua Xu, Xiaoyang Sun, Beicheng Sun, and Xuehao Wang conceived and designed the experiments. Bin Wang, Shushan Yan, and Xiaochen Wang performed the experiments and collected data. Weijie Wang, Donghua Xu, Bin Wang, and Shushan Yan analyzed the data. Xiaochen Wang and Yin Yin contributed to reagents/materials/analysis tools. Weijie Wang, Donghua Xu, Xiaoyang Sun, and Beicheng Sun wrote the paper. Weijie Wang, Donghua Xu, Bin Wang, Shushan Yan, and Xiaochen Wang equally contributed to this work.

References

[1] P. C. Robinson and S. Horsburgh, “Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities,” Maturitas, vol. 78, no. 4, pp. 245–251, 2014.
[2] P. Richette and T. Bardin, “Gout,” The Lancet, vol. 375, no. 9711, pp. 318–328, 2010.
[3] M. Doherty, “New insights into the epidemiology of gout,” Rheumatology, vol. 48, supplement 2, pp. i2–i8, 2009.
[4] Y. Cai, Y. H. Peng, Z. Tang et al., “Association of Toll-like receptor 2 polymorphisms with gout,” Biomedical Reports, vol. 2, no. 2, pp. 292–296, 2014.
[5] D. Grassi, L. Ferri, G. Desideri et al., “Chronic hyperuricemia, uric acid deposit and cardiovascular risk,” Current Pharmaceutical Design, vol. 19, no. 13, pp. 2432–2438, 2013.
[6] C.-F. Kuo, S.-F. Luo, L.-C. See, L.-J. Chou, Y.-F. Fang, and K.-H. Yu, “Increased risk of cancer among gout patients: a nationwide population study,” Joint Bone Spine, vol. 79, no. 4, pp. 375–378, 2012.
[7] A. M. Strasak, K. Rapp, W. Hilbe et al., “Serum uric acid and risk of cancer mortality in a large prospective male cohort,” Cancer Causes and Control, vol. 18, no. 9, pp. 1021–1029, 2007.
[8] A. M. Strasak, K. Rapp, W. Hilbe et al., “The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women,” Annals of Oncology, vol. 18, no. 11, pp. 1893–1897, 2007.
[9] M. A. Fini, A. Elias, R. J. Johnson, and R. M. Wright, “Contribution of uric acid to cancer risk, recurrence, and mortality,” Clinical and Translation Medicine, vol. 1, no. 1, p. 16, 2012.
[10] L. Baeksgaard and J. B. Sørensen, “Acute tumor lysis syndrome in solid tumors: a case report and review of the literature,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 3, pp. 187–192, 2003.
[11] S. G. Wannamethee, “Serum uric acid and risk of coronary heart disease,” Current Pharmaceutical Design, vol. 11, no. 32, pp. 4125–4132, 2005.
[12] B. N. Ames, R. Cathcart, E. Schwiers, and P. Hochstein, “Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 11, pp. 6858–6862, 1981.
[13] C. J. Chen, J. H. Yen, and S. J. Chang, "Gout patients have an increased risk of developing most cancers, especially urological cancers," Scandinavian Journal of Rheumatology, 2014.

[14] W. G. Cochran, "The comparison of percentages in matched samples," Biometrika, vol. 37, no. 3-4, pp. 256–266, 1950.

[15] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses," British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.

[16] N. Mantel and W. Haenszel, "Statistical aspects of the analysis of data from retrospective studies of disease," Journal of the National Cancer Institute, vol. 22, no. 4, pp. 719–748, 1959.

[17] R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.

[18] M. Egger, G. D. Smith, M. Schneider, and C. Minder, "Bias in meta-analysis detected by a simple, graphical test," The British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997.

[19] A. E. Stuck, L. Z. Rubensteins, and D. Wieland, "Bias in meta-analysis detected by a simple, graphical test: asymmetry detected in funnel plot was probably due to true heterogeneity," British Medical Journal, vol. 316, no. 7129, pp. 469–471, 1998.

[20] P. Boffetta, C. Nordenvall, O. Nyren, and W. Ye, "A prospective study of gout and cancer," European Journal of Cancer Prevention, vol. 18, no. 2, pp. 127–132, 2009.

[21] K.-H. Yu, C.-F. Kuo, S.-F. Luo et al., "Risk of end-stage renal disease associated with gout: a nationwide population study," Arthritis Research and Therapy, vol. 14, no. 2, article R83, 2012.

[22] C.-F. Kuo, K.-H. Yu, L.-C. See et al., "Risk of myocardial infarction among patients with gout: a nationwide poputation-based study," Rheumatology, vol. 52, no. 1, pp. 111–117, 2013.

[23] J. M. Fraile, R. J. Torres, M. E. de Miguel et al., "Metabolic syndrome characteristics in gout patients," Nucleosides, Nucleotides and Nucleic Acids, vol. 29, no. 4–6, pp. 325–329, 2010.

[24] J. G. Puig and M. A. Martinez, "Hyperuricemia, gout and the metabolic syndrome," Current Opinion in Rheumatology, vol. 20, no. 2, pp. 187–191, 2008.

[25] V. C. Kok, J.-T. Horng, H.-L. Lin, Y.-C. Chen, Y.-J. Chen, and K. F. Cheng, "Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan," BMC Cardiovascular Disorders, vol. 12, article 108, 2012.

[26] D. B. Peden, R. Hohman, M. E. Brown et al., "Uric acid is a major antioxidant in human nasal airway secretions," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 19, pp. 7638–7642, 1990.

[27] A. E. Mirrakhimov, A. M. Ali, M. Khan, and A. Barbaryan, "Tumor lysis syndrome in solid tumors: an up to date review of the literature," Rare Tumors, vol. 6, article 5389, no. 2, 2014.

[28] S. Jeha, "Tumor lysis syndrome," Seminars in Hematology, vol. 38, no. 4, supplement 10, pp. 4–8, 2001.

[29] A. Mazza, E. Casiglia, R. Scarpa et al., "Predictors of cancer mortality in elderly subjects," European Journal of Epidemiology, vol. 15, no. 5, pp. 421–427, 1999.

[30] M. Tomita, S. Mizuno, H. Yamanaka et al., "Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers," Journal of Epidemiology, vol. 10, no. 6, pp. 403–409, 2000.

[31] L. N. Kolonel, C. Yoshizawa, A. M. Nomura, and G. N. Stemmermann, "Relationship of serum uric acid to cancer occurrence in a prospective male cohort," Cancer Epidemiology Biomarkers and Prevention, vol. 3, no. 3, pp. 225–228, 1994.